Drugs for Neglected Diseases initiative

News

Non-profit DNDi preps phase 3 trials for dengue antibody

Non-profit DNDi has licensed a dengue therapy from India's SII, paving the way for a phase 3 trial in Malaysia, Thailand, and Brazil.

News

Apogee buy delivers eczema trial win for AbbVie

AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Drugs for Neglected Diseases initiative

Editor's Picks